CVM Overview

CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).

Wall Street analysts forecast CVM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVM is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

CEL-SCI Corp revenue for the last quarter amounts to 0.00 USD, decreased

CEL-SCI Corp. EPS for the last quarter amounts to -0.67 USD, decreased -71.24

CEL-SCI Corp (CVM) has 44 emplpoyees as of June 21 2026.

Today CVM has the market capitalization of 18.18M USD.